Who invested in Intarcia Therapeutics

13 rounds we have observed, with the 14 investors named in them. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

BiotechHealthcare

Valuation: $4.0B, Apr 2022

Funding summaryUpdated 26 Oct 2026

$1.1Braised across 13 rounds since 2003, from 13 sources

$43MSeries D$50MSeries E$50MSeries B$9.0MSeries B$14MVenture$5.0MSeries B$46MDebt$46MDebt$50MDebt$160MSeries C$200MGrowth$225MGrowth$215MRound

Latest round: Round, $215MSept 2016
Biggest round: $225MGrowth · Apr 2015
Investors: 14

See who backed them

The funding story

Each circle is a round, placed by date and sized by amount. The line above is the running total.

2003200520072009201120132015

$43MSeries D$50MSeries E$50MSeries B$9.0MSeries B$14MVenture$46MDebt$46MDebt$50MDebt$200MGrowth$225MGrowth$215MRound

First round: Series D, $43M
Biggest round: $225M
Usual gap between rounds: 15 months

The rounds

Sept 2016
Round$215M1 new
- Lucion Venture Capital Group
Reported by FinSMEsSEC filing: $184M sold, first sale Sept 2016
Apr 2015
Growth$225M
No investor was named in the report.
From a historical funding record
Apr 2014
Growth$200M5 new1 returning
- RA Capital Management
- Foresite Capital
- New Leaf Venture Partners
- Farallon Capital Management
- Fred Alger Management
- Quilvest Ventures
From a historical funding recordSEC filing: $200M sold, first sale Mar 2014
Nov 2012
Series C$160M1 new2 returning
Reported by pevc.dowjones.comSEC filing: $699K sold, first sale Nov 2012
Nov 2012
Debt$50M3 returning
Reported by intarcia.comSEC filing: $699K sold, first sale Nov 2012
Aug 2012
Debt$46M
No investor was named in the report.
Reported by sec.govSEC filing: $46M sold, first sale Aug 2010
Jun 2011
Debt$46M
No investor was named in the report.
Reported by sec.govSEC filing: $27M sold, first sale Aug 2010
Sept 2010
Series B$5.0M3 returning
Reported by venturebeat.comSEC filing: $5.0M sold, first sale Aug 2010
May 2010
Venture$14M
No investor was named in the report.
Reported by sec.govSEC filing: $14M sold, first sale Mar 2010
Jan 2010
Series B$9.0M
No investor was named in the report.
Reported by sec.govSEC filing: $9.0M sold, first sale Nov 2009
Mar 2007
Series B$50M3 new4 returning
Reported by venturebeat.com
Dec 2004
Series E$50M3 new1 returning
From a historical funding record
Jan 2003
Series D$43M1 new
- Venrock
From a historical funding record

Who was in which round

The busiest backers across the latest rounds. A filled square is a round they joined; a dark one, a round they led.

Series B2010Debt2011Debt2012Debt2012Series C2012Growth2014Growth2015Round2016

Venrock

New Enterprise Associates

New Leaf Venture Partners

GGV Capital

Alta Partners

RA Capital Management

Foresite Capital

Omega Funds

Marker

Farallon Capital Management

Everyone who backed them

VenrockVC firm6rounds

New Enterprise AssociatesVC firm4rounds

New Leaf Venture PartnersVC firm4rounds

GGV CapitalVC firm3rounds

Alta PartnersVC firm2rounds

RA Capital ManagementPrivate equity1round

Foresite CapitalPrivate equity1round

Omega FundsVC firm1round

MarkerVC firm1round

Farallon Capital ManagementAsset manager1round

Quilvest SwitzerlandFamily office1round

Fred Alger ManagementGrowth equity1round

Lucion Venture Capital Groupno record of our own yet1round

Quilvest Venturesno record of our own yet1round

Missing a round, or an investor who was in one? Tell us.

Also claim to have backed them

These 2 firms list Intarcia Therapeutics as a portfolio company on their own websites, but no report of a round names them. They are the firms' own claims, kept apart from the rounds above.

The Pritzker OrganizationFamily officePer its own site

Cloudstone Venture...VC firmPer its own site

Quick answers about Intarcia Therapeutics

Who invested in Intarcia Therapeutics?

Intarcia Therapeutics's investors include Venrock, New Enterprise Associates, New Leaf Venture Partners, GGV Capital and Alta Partners, and 9 more on record.